Format

Send to

Choose Destination
J Viral Hepat. 2017 Oct;24(10):840-849. doi: 10.1111/jvh.12708. Epub 2017 May 25.

Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.

Author information

1
Department of Medicine 1, University Hospital, J.W. Goethe University, Frankfurt am Main, Germany.
2
Gastroenterology-Hepatology Center Kiel, Kiel, Germany.
3
Medical Department II, Gastroenterology, Hepatology, Infectiology, St. Josefs-Hospital, Wiesbaden, Germany.
4
Liver Unit, Asklepios Clinic St. Georg, IFI-Institute, Hamburg, Germany.
5
Center for Infectiology Berlin, Berlin, Germany.
6
Center for Interdisciplinary Medicine (CIM), Münster, Germany.
7
Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.
8
Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
9
Private Practice, Frankfurt am Main, Germany.
10
Hepatologie - Magdeburg, Magdeburg, Germany.
11
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
12
Leberzentrum am Checkpoint Berlin, Berlin, Germany.
13
Private Practice for Internal Medicine, Berlin, Germany.
14
Department of Medicine I, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
15
Infektiologikum, Frankfurt am Main, Germany.
16
Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany.
17
AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
18
Center for Gastroenterology and Hepatology, Herne.

Abstract

Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on direct-acting antiviral therapies. Patients with GT1/4 infection treated with OBV/PTV/r±DSV±RBV were analysed. Effectiveness was assessed by sustained virologic response in 558 patients who reached post-treatment week 12 (SVR12). Safety is reported in 1017 patients who initiated treatment. Of the patients, 892 (88%) had GT1 and 125 (12%) had GT4 infection. Prior treatment experience and cirrhosis were reported in 598 (59%) and 228 (22%) patients, respectively. Overall, SVR12 (mITT) was 96% (486/505) in GT1- and 100% (53/53) in GT4 patients. SVR12 rates were high across subgroups including patients with cirrhosis (95%, 123/129), patients with moderate to severe renal impairment (100%, 34/34), and subgroups excluded from registrational trials like patients ≥70 years (96%, 64/67) and failures to prior protease inhibitor treatment (96%, 46/48). Adverse events (AEs) and serious AEs were reported in 52% (525/1017) and 2% (21/1017) of patients, respectively, and led to treatment discontinuation in 1.5% (15/1017) of patients. OBV/PTV/r±DSV±RBV was effective and generally well tolerated for treatment of HCV infection in clinical practice.

KEYWORDS:

chronic hepatitis C; cirrhosis; dasabuvir; direct-acting antivirals; ombitasvir/paritaprevir/r

PMID:
28342229
DOI:
10.1111/jvh.12708
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center